Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
PMID: 18507527
2008
AIDS research and human retroviruses
Abstract: The secondary mutations showed the typical protease inhibitor resistance-associated pattern for non-subtype B viruses, M36I being the predominant mutation (92.5% in women, 100% in babies).
Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.
PMID: 18545158
2008
Journal of acquired immune deficiency syndromes (1999)
Abstract: These simulations documented that the G48E mutant interacted with PI resistance mutations (M46I, I54V, Q58E, and L63P) and with natural polymorphisms specific to subtype A1 (E35D, M36I, and R57K) that were present in the patient's virus.
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
PMID: 18625773
2008
Antimicrobial agents and chemotherapy
Abstract: Mutations at six residues were associated with a lower VR (E35D/G/K/N, M36I/L/V, Q58E, Q61D/E/G/H/N/R, H69I/K/N/Q/R/Y, and L89I/M/R/T/V), and one mutation was associated with a higher VR (F53L/W/Y).
Abstract: The genotypic score M36I/L/V-53L/W/Y + Q58E + H69I/K/N/Q/R/Y + L89I/M/R/T/V was selected as providing a strong association with VR.
Tipranavir resistance associated mutations in protease inhibitor-naive patients with HIV-1 subtype A/E infection.
Abstract: Patients with subtype A/E had higher prevalence of I13V (54% vs. 21%, P=0.011), M36I (96% vs. 53%, P<0.001), H69K (68% vs. 26%, P=0.001), and >2 TPV-RAMs (62% vs. 21%, P=0.002).
Abstract: The most common TPV-RAMs were M36I (88%), H69K (61%), and I13V (48%).
Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains.
PMID: 16762582
2007
International journal of infectious diseases
Abstract: The most frequent mutation was M36I (29 of 29 strains), followed by L63T, K20R, and L10V.
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
Abstract: The most common protease mutations that developed in tipranavir-treated individuals who experienced virologic failure were L10I/V/S, I13V, L33V/I/F, M36V/I/L V82T, V82L, and I84V.
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Method: In addition, the model was also adjusted on use of nelfinavir at baseline and on the number of PI mutations (L10IRVF, K20RM, M36I, A71VT, G73SA, V82AFTS, L90M) found to be associated with the virological response in univariate analyses in this subset of patients.
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
PMID: 17296739
2007
Antimicrobial agents and chemotherapy
Abstract: The Zephir mutation score included 12 IAS protease mutations associated with poorer virological response: L10I/F/R/V, L33F, M36I, M46I/L, I54L/M/T/V, I62V, L63P, A71I/L/V/T, G73A/C/F/T, V82A/F/S/T, I84V, L90M, and polymorphism mutations I13V, L19I, K55R, and L89M.
Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference.
PMID: 17411368
2007
AIDS research and human retroviruses
Abstract: The frequencies of minor mutations to protease inhibitors (PI) were I93L (71.4%), L63P (62.6%), V77I (62.6%), M36I/V (33.0%), A71T/V (22.0%), K20R (6.6%), G16E (6.6%), and L10I (5.5%).
Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
PMID: 17425479
2007
Expert opinion on pharmacotherapy
Abstract: The TPV mutation score includes L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D and I84V.
HIV mutation literature information.
PMID: 
2008
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT